Merck & Co., Inc. (MRK)
Merck's $1.3B Deal For Potential Autoimmune Disorder Candidate Is Relevant To Cullinan's Investigational Drug, Says Analyst
On Friday, Merck & Co Inc MRK agreed to acquire CN201, an investigational clinical-stage bispecific antibody for B-cell-associated diseases, from privately-held Curon Biopharmaceutical.
Merck to buy experimental drug targeting B-cell diseases for up to $1.3 billion
Merck said Friday it's has agreed to acquire an experimental drug targeting B-cell associated diseases for up to $1.3 billion.
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know
Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Merck says it's discontinuing a late-stage trial of a lung cancer treatment after high number of adverse events
Merck & Co. MRK, +1.21% said Thursday it's discontinuing a late-stage trial of a treatment for patients with extensive-stage small cell lung cancer after patients experienced a high rate of adverse events. The company said it's notifying study investigators of the decision and telling them patients should stop treatment, which was a fixed dose of vibostolimab, an anti-TIGIT antibody, and pembrolizumab, or Keytruda, Merck's blockbuster cancer drug, in combination with chemotherapy compared to atezolizumab in combination with chemotherapy.
Merck stops experimental lung cancer drug combo trial
Merck said on Thursday it had discontinued its trial of a combination of its experimental drug and blockbuster therapy Keytruda for the treatment of a type of lung cancer, after an interim analysis showed the drug was unlikely to succeed.
The 3 Best Biotech Stocks to Buy in August 2024
Amid the stock market turmoil, wagering on the best biotech stocks could be a savvy move. The stock market has been tumultuous lately, which could spur a pivot toward defensive biotech stocks.
Merck's Blockbuster Vaccine Gardasil Sales In China: Analyst Highlights Challenges and Opportunities
Goldman Sachs recently discussed with Joe Romanelli, President of Human Health International at Merck & Co Inc MRK, to review Gardasil's performance and future outlook in China.
Are You Looking for a High-Growth Dividend Stock?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes?
What Are the Hottest Biotech Stocks Right Now? 3 Top Picks.
Sometimes the best way to jump into an industry like biotech is to follow the popular trades. Though that may go against the common advice of avoiding hype cycles and the fear of missing out, seeing which biotech stocks are experiencing the highest 24-hour trading volumes can be a quick way to learn which catalysts are driving investors to the industry.
Should You Pick Merck Stock At $115 After A Q2 Beat?
Merck (NYSE: MRK) recently reported its Q2 results, with revenues and earnings exceeding our estimates. The company garnered $16.1 billion in revenue and adjusted earnings of $2.28 per share, compared to our estimates of $15.9 billion and $2.20, respectively.
Merck reports earlier-than-expected improvement in semiconductor market
Merck KGaA is seeing a faster-than-expected improvement in its semiconductor materials business, the German pharma and technology company said on Thursday.
Merck Analysts Slash Their Forecasts After Q2 Results
Merck & Co Inc MRK reported better-than-expected second-quarter earnings and sales results on Tuesday.
